World Alzheimer's Day 2021: The Power of Knowledge

World Alzheimer's Day is an international campaign organised by Alzheimer's Disease International to raise awareness and highlight issues faced by people affected by dementia. It takes place every year on September 21st and is the focus of World Alzheimer's Month.

Dementia is one of the biggest challenges we face, with nearly 50 million people living with dementia worldwide. Yet 2 out of every 3 people globally believe there is little or no understanding of dementia in their countries.The impact of World Alzheimer's Month is growing, but the stigmatisation and misinformation that surrounds dementia remains a global problem. To tackle this challenge, we need to collaborate and share best practice with one another.

In support of this year’s theme – ‘Know dementia, know Alzheimer's’ - Elsevier presents a curated, open access collection of over 70 journal articles and book chapters focused on shining a light on the warning signs of dementia and the importance of a timely diagnosis.

Elsevier,

Alzheimer's Disease Theranostics, January 2019, Pages 7-12

This book chapter advances SDGs 3 and 17 by focusing primarily on the recent developments in Alzheimer's Disease diagnosis and their merits and demerits, including development of blood and cerebrospinal fluid–based biomarkers, imaging tools such as MRI, fMRI, and PET, proteomics, etc.
Elsevier,

Diagnosis and Management in Dementia, Volume 1, August 2020, Pages 827-842

This book chapter advances SDGs 3 and 17 by discussing the potential impact of dementia on creativity, physical activity, and exercise participation and whether exercise and creativity may each exert individual effects on the maintenance and/or facilitation of cognitive health. This chapter explores the context of biological and theoretical mechanisms underlying dementia and provide recommendations for future research experiments unifying physical exercise and creative activities into tailored interventions designed to better comprehend this disease and perhaps counteract the devastating implications dementia prognoses present to optimal physical and mental functioning across the human life span.
Elsevier,

Diagnosis and Management in Dementia, Volume 1, August 2020, Pages 665-680

This book chapter advances SDGs 3 and 17 by describing how acute hospital settings can affect the care of patients with dementia. As well as changes to the physical hospital environment, this requires an enhanced focus on key strategies such as reliable identification of cognitive impairment, access to comprehensive geriatric assessment, prevention and management of delirium, and timely discharge planning are included in the chapter.
Elsevier,

Diagnosis and Management in Dementia, Volume 1, August 2020, Pages 147-164

This book chapter advances SDGs 3 and 17 by discussing available data regarding the effects of genetic variants on the clinical and pathological characteristics of “frontotemporal dementia” (FTD). The term “frontotemporal dementia” (FTD) defines a group of related diseases resulting from progressive degeneration of the temporal and frontal lobes. These areas play a significant role in decision-making, behavioral control, emotion, language, and motor functions.
Elsevier,

Diagnosis and Management in Dementia, Volume 1, August 2020, Pages 127-146

This book chapter advances SDGs 3 and 17 by focusing on providing a brief overview of genes associated with sporadic (late-onset) Alzheimer's disease (AD). Despite decades of research, no current and reliable test is currently available for the diagnosis of AD. Genetic biomarkers are promising for both diagnostic tools and tailored profiling therapy.
Elsevier,

Diagnosis and Management in Dementia, Volume 1, August 2020, Pages 3-15

This book chapter advances SDGs 3 and 17 by reviewing how to diagnosis mixed dementias.
Elsevier,

Neuropsychological Tools for Dementia, November 2020, Pages 377-382

This book chapter advances SDGs 3 and 17 by providing an overview of the characteristic features of neurodegenerative diseases, including AD and how to assess them to validate or to reject the suspected diagnosis.
Elsevier,

Assessments, Treatments and Modeling in Aging and Neurological Disease, May 2021, Pages 115-126

This book chapter advances SDGs 3 and 17 by summarizing the relation between AD, dementia and vascular disease.
Elsevier,

Diseases of the Nervous System (Second Edition), May 2021, Pages 81-107

This book chapter advances SDGs 3 and 17 by introducing the concept of aging, dementia and Alzheimer Disease including the basic science, treatment, mechanisms and clinical trials.
Elsevier,

Evidence-informed Approaches for Managing Dementia Transitions: Riding the Waves, Volume , 4 February 2020

This book chapter advances SDGs 3 and 17 by focusing on the need to establish equilibrium and well-being and is organized around eight themes using the acronym R-E-A-D-J-U-S-T. The chapter ties these themes with a call for more research and reinforcement for inclusion of the voices of people with dementia.

Pages